IMAVEC

This brand name is authorized in Estonia, Lithuania, South Africa, Turkey.

Active ingredients

The drug IMAVEC contains one active pharmaceutical ingredient (API):

1	Imatinib UNII 8A1O1M485B - IMATINIB MESYLATE
	Imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr-Abl tyrosine kinase at the in vitro, cellular and in vivo levels.
	Read more about Imatinib

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EA01	Imatinib	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EA BCR-ABL tyrosine kinase inhibitors
Discover more medicines within L01EA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1547883, 1547894, 1547906, 1547917, 1547928, 1547939, 1547940
LT	Valstybinė vaistų kontrolės tarnyba	1063761, 1063762, 1071888, 1071889, 1071890, 1071891, 1071892
TR	İlaç ve Tıbbi Cihaz Kurumu	8699828150527, 8699828150534
ZA	Health Products Regulatory Authority	42/34/0496